A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19 outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.
Epistemonikos ID: 09780e3d1bb26aabd6d00c68d8e219bfd5b53f06
First added on: Nov 05, 2020